United States — Food and Drug Administration & Bristol Myers Squibb
7 shared events · Importance 3 · Last updated Sep 01, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
Bristol Myers Squibb: Bristol Myers Squibb is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: Published the Complete Response Letter rejecting Replimune's BLA and earlier briefing documents questioning the IGNYTE study data, triggering the share decline that underpins the lawsuits.
Bristol Myers Squibb: Its PD-1 inhibitor Opdivo was the combination partner in the rejected RP1 BLA; the rejection is a minor setback to one combination program within a large diversified portfolio.
Jul 29, 2026 · 139 articles
Regulatory
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Bristol Myers Squibb: Bristol Myers Squibb, another KRAS inhibitor developer, is similarly affected by the competitive landscape.
Aug 26, 2026 · 92 articles
Business
United States — Food and Drug Administration: Reportedly rejected ITM-11's application over third-party manufacturing issues and approved Telix's Pixclara and Curium's Bexlutry; its approvals gate up to $250 million in milestone payments.
Bristol Myers Squibb: Cited as a recent acquirer of radiopharmaceutical assets, part of the broader M&A trend in the industry.
Sep 21, 2026 · 6 articles
Business
United States — Food and Drug Administration: The FDA declined to approve Lantheus' LNTH-2501 application due to manufacturing issues, a setback for Lantheus' pipeline.
Bristol Myers Squibb: Bristol Myers Squibb is mentioned as a prior acquirer in the sector, highlighting the trend of radiopharmaceutical consolidation.
Aug 03, 2026 · 7 articles
Tech
Bristol Myers Squibb: Bristol Myers Squibb is jointly developing pumitamig with BioNTech, which is being used in the clinical trial collaboration with Boehringer Ingelheim.
Apr 09, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Bristol Myers Squibb interact across events, view sentiment trends, and discover connected entities.
Open Dashboard